Dr. Agarwal on Remaining Challenges in mCSPC

Neeraj Agarwal, MD, remaining challenges in metastatic castration-sensitive prostate cancer.

Neeraj Agarwal, MD, professor of medicine, and director of the Genitourinary Oncology Program, Huntsman Cancer Institute, discusses remaining challenges in metastatic castration-sensitive prostate cancer (mCSPC).

The shift toward utilizing novel hormonal therapies in the frontline setting for men with mCSPC ​has resulted in a dramatic improvement in overall survival, without hindering quality of life​, explains Agarwal. Some of these therapies include apalutamide (Erleada), enzalutamide (Xtandi), and abiraterone ​acetate (Zytiga), Agarwal says.

However, patients with mCSPC ​who progress on these therapies ​represent a challenging population to treat ​with additional therapy. As such, future research efforts should aim to identify new targets​, as well as therapies with novel mechanisms of action, ​to meet the need of these patients, says Agarwal. Additionally, patients with mCSPCshould be treated as early as possible, Agarwal concludes.